Andrea Eleazar, MHS

Registry data show bulky lymphoma drives different treatment choices and mixed survival effects, highlighting the need to standardize tumor bulk definitions.

Nationwide data show CGP turnaround improves, but biopsy-to-order delays vary widely, slowing biomarker-driven care in lung and solid tumors.

Liso-cel CAR T plus ibrutinib delivers deep remissions and high uMRD in relapsed CLL/SLL after multiple therapies, with manageable safety.

South Korean cohort shows heavy drinking sharply raises liver cancer risk after 60, guiding age-tailored screening and prevention.

FDA grants orphan status to DLL3-targeting ADC zocilurtatug pelitecan, boosting hopes for new options in hard-to-treat neuroendocrine cancers.

FDA approves a new rituximab biosimilar, boosting CD20 therapy options and market competition for B-cell cancers and autoimmune diseases in the US.

After encouraging early data were released, the FDA fast-tracked olomorasib, an oral KRAS G12C inhibitor, for the treatment of previously treated advanced pancreatic cancer.

Phase 3 Asian trial shows acalabrutinib sharply improves progression-free survival vs chlorambucil-rituximab in untreated, medically unfit CLL patients with favorable safety.

Patients favor subcutaneous pembrolizumab for faster visits and comparable safety, signaling a convenient new option across solid tumors.

FDA orphan designation boosts enzomenib for ALL, as menin inhibitor trials show early responses and tolerable safety in relapsed leukemia.

FDA fast-tracks off-the-shelf CD19 CAR T cema-cel for MRD+ LBCL consolidation, as ALPHA3 data show strong MRD clearance with outpatient care.

Phase 3 results show intravesical cretostimogene drives durable complete responses and bladder preservation in BCG-unresponsive NMIBC.

Adding emavusertib to ibrutinib boosts response rates in relapsed/refractory PCNSL, including in BTKi-experienced patients, while safety monitoring addresses prior FDA hold concerns.

Monthly IVIG prophylaxis sharply lowers moderate infections in CLL with low IgG, suggesting better quality of life despite baseline Ig levels.

Phase 1/2 SIDNEY interim results show EO2463 boosts CD8 T cells, linking to longer PFS and responses in watch-and-wait patients with indolent NHL.

Ten-year RELEVANCE results show chemo-free R2 matches immunochemotherapy for advanced follicular lymphoma, with comparable survival and safety.

Chronic stress biomarker allostatic load links to higher under-50 cancer risk, offering a simple lab-based tool to improve prevention and screening.

Early trial shows off-the-shelf immunotherapy combo boosts responses in relapsed B-cell lymphoma with manageable CRS and safety.

Real-world data link vitamin D supplements to longer watch-and-wait time before CLL treatment, prompting fresh debate on delaying progression.

Survey reveals race and sex gaps in lymphoma trial barriers—travel, costs, complexity, and mistrust—pointing to navigators, decentralized visits, and reimbursement fixes.

Rising out-of-pocket costs push more adults to skip needed care, regardless of cancer history—highlighting financial toxicity and the need for smarter risk screening.

FDA clears perioperative pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer, boosting event-free and overall survival ahead of cystectomy.

FDA clears IND for UGN-501 oncolytic virus, launching phase 1 NMIBC trial to test intravesical safety and immune-driven tumor control.

CMS proposes deeper 340B drug payment cuts for hospitals, reshaping outpatient cancer economics, consolidation incentives, and patient cost-sharing.

Triplet therapy ziftomenib plus venetoclax/azacitidine boosts MRD-negative remissions in relapsed NPM1-mutated AML, hinting at earlier use.

Phase 3 MANGROVE shows chemo-free zanubrutinib plus rituximab extends PFS in untreated mantle cell lymphoma, with no new safety issues.

Phase 3 trial shows chemo-free epcoritamab plus lenalidomide cuts progression risk in relapsed DLBCL, with no new safety signals.

Genetic testing isn’t the finish line—learn how evolving risk models, dense breast guidance, and MCED screening may transform early cancer detection.

Ranjit Goudar, MD explains how community oncology practices are expanding hereditary cancer care through genetic testing, workflow redesign, and personalized prevention strategies.

NCCN adds ctDNA-MRD testing after cystectomy, using Signatera to identify MIBC patients who may benefit from adjuvant atezolizumab.